Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

CR Services Acquisition US LLC

Neither a doctor nor a teaching hospital

Research payments

$9,092,508

909 payments

Through program year 2025, CR Services Acquisition US LLC is reported as receiving $9,092,508 in research payments, across 909 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $5,084,385 682
2024 Research $4,008,123 227

Breakdown

Who paid Research payments · program years 2024–2025
  1. Moderna TX, Inc. $4,590,499 363 payments
  2. AbbVie, Inc. $1,608,966 259 payments
  3. Sanofi Pasteur Inc. $1,182,018 57 payments
  4. Eli Lilly and Company $1,128,761 23 payments
  5. Pfizer Inc. $465,295 39 payments
  6. Verona Pharma, Inc. $29,700 5 payments
  7. Sanofi US Services Inc. $26,335 21 payments
  8. GlaxoSmithKline, LLC. $14,000 4 payments
  9. Regeneron Pharmaceuticals, Inc. $12,324 94 payments
  10. Janssen Research & Development, LLC $10,450 6 payments
Studies the money was for Research payments · program years 2024–2025
  1. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $2,168,687 28 payments
  2. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $1,321,249 94 payments
  3. A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. $1,166,598 54 payments
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $477,642 4 payments
  5. A Phase 3 Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety of A 6Valent Ospabased Lyme Disease Vaccine Vla15 in Healthy Children 5 Through 17 Years of Age $444,941 25 payments
  6. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $441,225 71 payments
  7. A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa $330,573 17 payments
  8. BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $285,652 50 payments
  9. A Study of Tirzepatide (Ly3298176) Once Weekly in Adolescent Participants Who Have Obesity, Or Are Overweight With Weight-Related Comorbidities $233,404 2 payments
  10. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $226,671 21 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record